St. Jude Medical Inc.: In-Line Is Just Not Good Enough

Expectations may be the bigger challenge for St. Jude these days

Apr 16, 2014 at 6:30PM

It's hard to call it a bad thing when Wall Street likes a stock, but rising expectations can create problems of their own. St. Jude Medical (NYSE:STJ) seems to have done a good job of selling the Street on the idea that it has turned over a new leaf and that accelerating growth is around the corner.

Sell-side price targets are about 20% higher now than at the beginning of 2014, and the buy/hold/sell recommendation breakdown has moved from 11-10-3 to 14-8-2 over the past three months, though the EPS targets for 2014 and 2015 have hardly budged. That optimism may well explain why St. Jude's "good enough" first quarter wasn't quite good enough for investors.

A respectable performance
St. Jude reported constant currency revenue growth of nearly 4% for the quarter, coming in almost spot on with the sell-side target. CRM sales rose 3%, cardio rose 2%, and neuro rose 1%, while atrial fibrillation revenue rose 10%.

Margins and profits also closely matched expectations. Gross margin improved 120bp from last year and were within 10bp of the sell-side average. Operating income fell 1% this quarter but again were almost identical to sell-side expectations as the operating margin declined 70bp.

Likely still gaining share in CRM
St. Jude's CRM business continues to perform quite well, and though Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) have not yet reported for this cycle, my expectation is that St. Jude will continue to have gained share. St. Jude has done surprisingly well in the high-energy segment of the market (close to one-third of the market), where its quadripolar system has led to almost 40% share in de novo CRT-D.

Medtronic and Boston Scientific aren't going to let this stand, but St. Jude has additional levers for growth even as they close the gap in quad. Nanostim (a leadless pacemaker) should be a significant product down the line and the recent FDA approvals of the Allure Quadra CRT-P, Assurity, and Endurity pacemakers should maintain some momentum in the business. Perhaps just as important, these late March approvals suggest that the FDA is satisfied with the company's progress on its warning letters.

Is the best yet to come with a-fib?
St. Jude lagged Johnson & Johnson (NYSE:JNJ) in a-fib this quarter, as Johnson & Johnson saw 15% growth in its Biosense business this quarter. Johnson & Johnson is already the market leader in a-fib with better than 40% share, but I don't think that St. Jude (which is in second place with nearly one-third share) lost as much ground as feared.

The real issue for St. Jude now is getting TactiCath, a product it acquired in the deal for EndoSense, on the market. St. Jude is well behind the back in ablation catheters (#4 with 14% share) and Johnson & Johnson has made the most of having the only ablation catheter on the market with a specific AF indication. Product features like the TactiCath's force-sensing capability are certainly relevant, but just having a credible catheter product could do a lot of good. In contrast, MediGuide seems to be falling short of management's once-enthusiastic projections.

New products need to hit the ground running
One of the lingering issues at St. Jude for many years has been that management can spin a good tale about how good the growth prospects can be in three years time, but when those years actually roll around the results don't measure up. At the risk of speaking for the bears, I believe that is a key to the current bearish thesis – that St. Jude's current pipeline opportunities will once again come up short on delivery.

It's certainly true that not a lot is expected of the company's Portico transcatheter heart valve. Edwards Lifesciences is already well ahead in the market and Medtronic offers a greater range of product sizes, though recent litigation between Edwards and Medtronic may keep the latter off the market in the U.S. for a few years. Renal denervation is another growth market that has lost its luster more recently with Medtronic's clinical trial failure and St. Jude hasn't really given a clear sense of their plans here moving forward.

On a more promising here-and-now note, St. Jude did also recently get FDA approval for its Protege spinal cord stimulation device. This is the first new neuro device from the company in over five years (due in part to issues with FDA warning letters) and it should help reignite a business that has been losing momentum and market share to Medtronic and Boston Scientific.

The Bottom Line
On balance I am fairly bullish about St. Jude as a company, but I still believe that the stock has gotten a little ahead of itself. Long-term revenue growth of 5% and FCF growth of nearly 11% would make this one of the best large-cap growth stories, but it still only supports a fair value in the mid-$50's with a required rate of return of 9.5%. It would also take an EV/revenue multiple of four times to get an interesting target on the shares by that methodology, and I think that's a bit of a stretch given the historical averages for companies of this size. All told, I still like St. Jude, but not enough to earn sub-par returns on the shares.

St. Jude's dividend is solid-but what are the top dividend stocks for the next decade?
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.


Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers